Epigenomic and enhancer dysregulation in uterine leiomyomas

Keyphrases

• Uterine Leiomyoma 100%
• Dysregulation 100%
• Epigenomics 100%
• Uterine Fibroids 50%
• Fibroids 50%
• Leiomyoma 50%
• Histone Modification 33%
• Aberrant DNA Methylation 33%
• Stem Cells 16%
• Gene Expression 16%
• Angiogenesis 16%
• DNA Methylation (DNAm) 16%
• Molecular Mechanism 16%
• Genetic Factors 16%
• Common Disease 16%
• Apoptosis 16%
• Racial Disparities 16%
• Overexpression 16%
• Gene Function 16%
• Tumor 16%
• Women of Reproductive Age 16%
• Increased Incidence 16%
• Etiology 16%
• Environmental Factors 16%
• Symptom Severity 16%
• Stem Cell Differentiation 16%
• Extracellular Matrix Deposition 16%
• Treatment Options 16%
• DNA Sequencing 16%
• Fast-growing 16%
• Epigenome 16%
• HMGA2 16%
• Aberrations 16%
• Chromatin Modification 16%
• Epigenetic Modification 16%
• White Women 16%
• Dysregulated Genes 16%
• Non-invasive Treatment 16%
• Translational Implications 16%
• Tumor Suppression 16%
• MED12 16%
• DNA Structures 16%
• Black Women 16%
• High Prevalence 16%
• Promoter Methylation 16%
• Histone Post-translational Modifications 16%
• Non-surgical Treatment 16%
• Gynecological Tumors 16%
• Key Discovery 16%
• Gene Dysregulation 16%
• Cancer Pathways 16%
• DNA Methylation Age 16%
• Extracellular Matrix Organization 16%
• Dysregulated Gene Expression 16%
• Epigenomic Features 16%
• Black Population 16%
• Early Age of Onset 16%
• Space Constraints 16%
• 3D Shape 16%
• Apologizing 16%
• Menopausal Age 16%
• PubMed Search 16%
• Overexpressed Genes 16%
• Structure Modification 16%
• DNA Methylation Analysis 16%
• Uterine Myoma 16%
• Histone Tail Modifications 16%
• Nucleosomal Histones 16%
• Gene Architecture 16%
• 3D Chromatin Structure 16%
• Chemical Alteration 16%
• Contact Strength 16%
• Histone Exchange 16%

Medicine and Dentistry

• Enhancer Region 100%
• Uterine Fibroid 100%
• Histone 40%
• DNA Methylation 40%
• Promoter Region 30%
• Epigenomics 30%
• Angioleiomyoma 30%
• Gene Expression 20%
• Stem Cell 20%
• Extracellular Matrix 20%
• Diseases 20%
• Histone Modification 20%
• Prevalence 10%
• Neoplasm 10%
• Angiogenesis 10%
• Programmed Cell Death 10%
• Racial Disparity 10%
• Cell Differentiation 10%
• DNA Sequence 10%
• Cancer Inhibition 10%
• Growth, Development and Aging 10%
• Malignant Neoplasm 10%
• Onset Age 10%
• Non Invasive Procedure 10%
• Gene Function 10%
• Conservative Treatment 10%
• DNA Structure 10%
• Mediator Complex 10%
• Chromatin Structure 10%
• Cell Signaling Pathway 10%
• Black Population 10%
• Base 10%
• Environmental Factor 10%
• Tail 10%
• Benign Female Genital Tract Tumor 10%
• Methylation 10%
• Post-Translational Modification 10%